PreprintCited by 897Epigenetics and DNA MethylationChromatin Remodeling and CancerGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 64 of the 68 references it cites were found in a registry or an index.

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Open access

Tan, Jing, Yang, Xiaojing, Zhuang, Li, Jiang, Xia, Chen, Wei, Lee, Puay Leng, Karuturi, R.K. Murthy, Tan, Patrick Boon Ooi, Liu, Edison T., Yu, Qiang·2007·Genes & Development

DOI 10.1101/gad.1524107PMC PMC1855231

Open this paper in CoChat — free account Open PDF

Abstract

Polycomb-repressive complex 2 (PRC2)-mediated histone methylation plays an important role in aberrant cancer gene silencing and is a potential target for cancer therapy. Here we show that S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A (DZNep) induces efficient apoptotic cell death in cancer cells but not in normal cells. We found that DZNep effectively depleted cellular levels of PRC2 components EZH2, SUZ12, and EED and inhibited associated histone H3 Lys 27 methylation (but not H3 Lys 9 methylation). By integrating RNA interference (RNAi), genome-wide expression analysis, and chromatin immunoprecipitation (ChIP) studies, we have identified a prominent set of genes selectively repressed by PRC2 in breast cancer that can be reactivated by DZNep. We further demonstrate that the preferential reactivation of a set of these genes by DZNep, including a novel apoptosis affector, FBXO32 , contributes to DZNep-induced apoptosis in breast cancer cells. Our results demonstrate the unique feature of DZNep as a novel chromatin remodeling compound and suggest that pharmacologic reversal of PRC2-mediated gene repression by DZNep may constitute a novel approach for cancer therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.1524107

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1
Beisel, C., Imhof, A., Greene, J., Kremmer, E., & Sauer, F. (2002) · Nature · doi:10.1038/nature01126 · Cited by 310
Retracted
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Regulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845 · cited 1×
“In contrast, histone H3 trimethylation at Lys 9 (H3-K9me3)—which is mediated by another histone MTase, Suv39h1 (Rea et al. 2000; Peters et al. 2001; Lehnertz et al. 2003)—was not affected by DZNep treatment.”
Background
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Polycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,568
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1279 · Cited by 2,404
Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R., Chevalier, B. S., Johnstone, S. E., Cole, M. F., Isono, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.043 · Cited by 2,296
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204

Show all 68 references

Sorted by citations

Items 601–700 of 897

The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines
Schmidt, A., Behrendt, L., Eybe, J., Warmann, S. W., Schleicher, S., Fuchs, J., & Schmid, E. (2021) · Cancers · doi:10.3390/cancers14010041 · Cited by 16
3-Deazaadenosine alleviates senescence to promote cellular fitness and cell therapy efficiency in mice
Guerrero, A., Innes, A. J., Roux, P., Buisman, S. C., Jung, J., Ortet, L., Moiseeva, V., Wagner, V., Robinson, L. J., Ausema, A., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00279-9 · Cited by 15
Advances on Epigenetic Drugs for Pediatric Brain Tumors
Skouras, P., Markouli, M., Strepkos, D., & Piperi, C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220922150456 · Cited by 16
Epigenetic Abnormalities in Chondrosarcoma
Bereza, M., Dembiński, M., Zając, A. E., Piątkowski, J., Dudzisz‐Śledź, M., Rutkowski, P. L., & Czarnecka, A. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054539 · Cited by 18
Lysine and arginine methylation of transcription factors
Giaimo, B. D., Ferrante, F., & Borggrefe, T. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05531-6 · Cited by 17
Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer
Tomao, F., Papa, A., Rossi, L., Caruso, D., Zoratto, F., Panici, P. B., & Tomao, F. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.839657 · Cited by 16
Histone modifications patterns in tissues and tumours from acute promyelocytic leukemia xenograft model in response to combined epigenetic therapy
Valiulienė, G., Treigytė, G., Savickienė, J., Matuzevičius, D., Alksnė, M., Jarašienė, R., Bukelskienė, V., Navakauskas, D., & Navakauskienė, R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.01.044 · Cited by 16
Epigenetic modifications promote the expression of the orphan nuclear receptor NR0B1 in human lung adenocarcinoma cells
Lu, Y., Liu, Y., Liao, S., Tu, W., Shen, Y., Yan, Y., Tao, D., Ma, Y., Ma, Y., Yang, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9012 · Cited by 16
Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening
Schröder, M., Loos, S., Naumann, S. K., Bachran, C., Krötschel, M., Umansky, V., Helming, L., & Swee, L. K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1258503 · Cited by 16
Transcriptional suppression of Dicer by HOXB‐AS3/EZH2 complex dictates sorafenib resistance and cancer stemness
Tseng, C., Chen, L., Wang, H., Liu, Y., & Shiah, S. (2022) · Cancer Science · doi:10.1111/cas.15319 · Cited by 16
Oncoepigenomics: Making histone lysine methylation count
DeCarlo, D., & Hadden, M. K. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.08.010 · Cited by 17
BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes
Zaiken, M. C., Flynn, R. P., Paz, K. G., Rhee, S. Y., Jin, S., Mohamed, F. A., Saha, A., Thangavelu, G., Park, P. M. C., Hemming, M. L., et al. (2022) · Blood · doi:10.1182/blood.2021014557 · Cited by 16
Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression
Gautam, N., Kaur, M., & Kaur, S. (2020) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1090_19 · Cited by 16
Histone Modifications, Stem Cells and Prostate Cancer
Crea, F., Clermont, P., Mai, A., & Helgason, C. D. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990522 · Cited by 16
Epigenetic reprogramming in gastrointestinal cancer: biology and translational perspectives
Wang, Y., Liu, H., Zhang, M., Xu, J., Zheng, L., Liu, P., Chen, J., Liu, H., & Chen, C. (2024) · MedComm · doi:10.1002/mco2.670 · Cited by 17
Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities
Woźniak, M., & Czyż, M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241306026 · Cited by 19
Histone methylation can either promote or reduce cellular radiosensitivity by regulating DNA repair pathways
Zhou, Y., & Shao, C. (2020) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2020.108362 · Cited by 14
Oncogene or Tumor Suppressor: The Coordinative Role of Lysine Methyltransferase SET7/9 in Cancer Development and the Related Mechanisms
Gu, Y., Zhang, X., Yu, W., & Dong, W. (2022) · Journal of Cancer · doi:10.7150/jca.57663 · Cited by 15
Polycomb repressor complex: Its function in human cancer and therapeutic target strategy
Liu, J., Fan, H., Liang, X., & Chen, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115897 · Cited by 17
3-Deazaneplanocin A (DZNep): A Drug That Deserves a Second Look
Márquez, V. E. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01566 · Cited by 15
Metabolic perturbation of epigenome by inhibiting S -adenosylhomocysteine hydrolase elicits senescence through DNA damage response in hepatoma cells
Wu, G., Wang, N., Luo, Y., Zhang, Y., Wang, P., Zhu, Z., Gao, Y., Zhi, D., & Yang, B. (2017) · Tumor Biology · doi:10.1177/1010428317699117 · Cited by 17
Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice
Lhuissier, E., Aury‐Landas, J., Bouët, V., Bazille, C., Repessé, Y., Fréret, T., Boumédiene, K., & Baugé, C. (2018) · Oncotarget · doi:10.18632/oncotarget.25062 · Cited by 15
Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators
Danishuddin, M., Subbarao, N., Faheem, M., & Khan, S. N. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.002 · Cited by 15
RNA Interference in the Treatment of Colon Cancer
Prados, J. C., Melguizo, C., Roldan, H., Alvarez, P. J., Ortíz, R., Arias, J. L., & Aránega, A. (2013) · BioDrugs · doi:10.1007/s40259-013-0019-4 · Cited by 15
Cell‐Based Proteome Profiling Using an Affinity‐Based Probe (AfBP) Derived from 3‐Deazaneplanocin A (DzNep)
Tam, E. K. W., Li, Z., Goh, Y. L., Cheng, X., Wong, S. Y., Santhanakrishnan, S., Chai, C. L. L., & Yao, S. Q. (2013) · Chemistry - An Asian Journal · doi:10.1002/asia.201300303 · Cited by 15
Methyltransferase Inhibitor Adenosine Dialdehyde Suppresses Androgen Receptor Expression and Prostate Cancer Growth
Shiota, M., Takeuchi, A., Yokomizo, A., Kashiwagi, E., Tatsugami, K., & Naito, S. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.02.2553 · Cited by 15
Inhibition of histone methyltransferase EZH2 ameliorates early acute renal allograft rejection in rats
Li, L., Zhang, Y., Xu, M., Rong, R., Wang, J., & Zhu, T. (2016) · BMC Immunology · doi:10.1186/s12865-016-0179-3 · Cited by 15
A role for KMT1c in monocyte to dendritic cell differentiation
Wierda, R. J., Goedhart, M., van Eggermond, M. C. J. A., Muggen, A. F., Miggelbrink, X. M., Geutskens, S. B., van Zwet, E. W., Haasnoot, G. W., & van den Elsen, P. J. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.03.017 · Cited by 15
Correction: CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells
Yang, X., Karuturi, R. K. M., Sun, F., Aau, M., Yu, K., Shao, R., Miller, L. D., Tan, P. B. O., & Yu, Q. (2009) · PLoS ONE · doi:10.1371/annotation/e70583a2-3581-4848-b1e3-b518ac07d3a6 · Cited by 15
Self-citation
Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
Dagdemir, A., Judes, G., Lebert, A., Echegut, M., Karslı-Çeppioğlu, S., Rifai, K. T., Daures, M., Ngollo, M., Dubois, L., Penault-Llorca, F. M., et al. (2016) · PubMed · Cited by 14
Mechanisms for enhancing cellular reprogramming
Soufi, A. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.12.007 · Cited by 14
Histone Methylases as Novel Drug Targets: Developing Inhibitors of EZH2
Baugé, C., Bazille, C., Girard, N., Lhuissier, E., & Boumédiene, K. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.123 · Cited by 16
MicroRNA-506-3p inhibits colorectal cancer cell proliferation through targeting enhancer of zeste homologue 2
Ai, L., Luo, X., Yan, X., & Jiang, S. (2021) · Bioengineered · doi:10.1080/21655979.2021.1951930 · Cited by 14
Inhibition of SIRT1 Increases EZH2 Protein Level and Enhances the Repression of EZH2 on Target Gene Expression
Lu, L., Li, L., Lu, X. Y., Wu, X., Liu, D., & Liang, C. (2011) · Chinese Medical Sciences Journal · doi:10.1016/s1001-9294(11)60024-2 · Cited by 14
Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update
Hatzimichael, E. C., Lagos, K. G., Sim, V., Briasoulis, E. C., & Crook, T. (2014) · Europe PMC (PubMed Central) · doi:10.17877/de290r-6936 · Cited by 14
Chromatin changes trigger laminin genes dysregulation in aging kidneys
Denisenko, O. N., Mar, D., Trawczynski, M., & Bomsztyk, K. (2018) · Aging · doi:10.18632/aging.101453 · Cited by 14
Aberrant DNA methylation in human cancers
Li, W., & Chen, B.-F. (2013) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-013-1201-0 · Cited by 14
Roles of F-box proteins in human digestive system tumors (Review)
Gong, J., Lv, L., & Huo, J. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2684 · Cited by 13
Histone Methylation in Myelodysplastic Syndromes
Wei, Y., Gañán‐Gómez, I., Dimicoli, S., McCay, S., & Garcia‐Manero, G. (2011) · Epigenomics · doi:10.2217/epi.11.9 · Cited by 13
Therapeutic Advances in Hematology
Kolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Cited by 13
Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers
Hanif, E. A. M., & Shah, S. A. (2018) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2018.19.12.3341 · Cited by 13
IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2
Sperling, F., Misiak, D., Hüttelmaier, S., Michl, P., & Griesmann, H. (2022) · Cancers · doi:10.3390/cancers14092121 · Cited by 13
DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine
Zhang, G., Wang, Z., Song, P., & Zhan, X. (2022) · The EPMA Journal · doi:10.1007/s13167-022-00300-6 · Cited by 12
The Transcription Factor Sterile Alpha Motif (SAM) Pointed Domain-containing ETS Transcription Factor (SPDEF) Is Required for E-cadherin Expression in Prostate Cancer Cells
Pal, M., Koul, S., & Koul, H. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434225 · Cited by 13
Retracted
Role of Enhancer of Zeste Homolog 2 Polycomb Protein and Its Significance in Tumor Progression and Cell Differentiation
Marchesi, I., & Bagell, L. (2013) · InTech eBooks · doi:10.5772/55370 · Cited by 15
Patho-Epigenetics of Disease
Minárovits, J., & Niller, H. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3345-3 · Cited by 13
A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention
Svrlanska, A., Reichel, A., Schilling, E.-M., Scherer, M., Stamminger, T., & Reuter, N. (2019) · Journal of Virology · doi:10.1128/jvi.02143-18 · Cited by 16
Epigenetic approaches to cancer therapy
Pollock, R. M., & Richon, V. M. (2009) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2010.04.002 · Cited by 13
LATS2 Positively Regulates Polycomb Repressive Complex 2
Torigata, K., Okuzaki, D., Mukai, S., Hatanaka, A., Ohka, F., Motooka, D., Nakamura, S., Ohkawa, Y., Yabuta, N., Kondo, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158562 · Cited by 13
Dual-target EZH2 inhibitor: latest advances in medicinal chemistry
Wei, L., Mei, D., Hu, S., & Du, S. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2380243 · Cited by 13
DZNep inhibits Hif‑1α and Wnt signalling molecules to attenuate the proliferation and invasion of BGC‑823 gastric cancer cells
Huang, R., Jin, X., Gao, Y., Yuan, H., Wang, F., & Cao, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.10769 · Cited by 12
Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia
Yang, C. J., Gu, Y., Ge, Z., & Song, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911393 · Cited by 12
Epstein–Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype
Ng, S., Ohshima, K., Selvarajan, V., Huang, G., Choo, S., Miyoshi, H., Shimizu, N., Reghunathan, R., Chua, H.-C., Yeoh, A. E. J., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.983099 · Cited by 12
Self-citation
Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome
Cheng, J. X., Anastasi, J., Watanabe, K. Q., Kleinbrink, E. L., Grimley, E. C., Knibbs, R., Shen, Q. J., & Vardiman, J. W. (2013) · Leukemia · doi:10.1038/leu.2013.45 · Cited by 12
Epigenetic Deregulation of MicroRNAs in Rhabdomyosarcoma and Neuroblastoma and Translational Perspectives
Romania, P., Bertaina, A., Bracaglia, G., Locatelli, F., Fruci, D., & Rota, R. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131216554 · Cited by 12
Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay
Murashima, A., Shinjo, K., Katsushima, K., Onuki, T., Kondoh, Y., Osada, H., Kagaya, N., Shin‐ya, K., Kimurâ, H., Yoshida, M., et al. (2019) · The Journal of Biochemistry · doi:10.1093/jb/mvz007 · Cited by 12
Epigenetic Regulation of Chromatin in Prostate Cancer
Natesan, R., Aras, S., Effron, S. S., & Asangani, I. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_17 · Cited by 12
Histone méthyltransférases
Chaib, H., Prébet, T., Vey, N., & Collette, Y. (2011) · médecine/sciences · doi:10.1051/medsci/2011278014 · Cited by 12
Decoding the Epigenome of Breast Cancer
Cortellesi, E., Savini, I., Veneziano, M., Gambacurta, A., Catani, M. V., & Gasperi, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062605 · Cited by 11
Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche
Rouger, J., Milano, F., Cahu, J., DaCosta, L., Martens, A. C., Renoir, J., & Sola, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107009 · Cited by 11
Unravelling the transcriptional responses of TGF‐β: Smad3 and EZH2 constitute a regulatory switch that controls neuroretinal epithelial cell fate specification
Andrews, D. C., Oliviero, G., Chiara, L. D., Watson, A., Rochford, E., Wynne, K. J., Kennedy, C., Clerkin, S., Doyle, B., Godson, C., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201800566rr · Cited by 11
Targeting Leukemia-Initiating Cells in Acute Lymphoblastic Leukemia
Tamiro, F., Weng, A. P., & Giambra, V. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2571 · Cited by 10
Personalized Medicine for Neuroblastoma: Moving from Static Genotypes to Dynamic Simulations of Drug Response
Han, J. Z. R., Hastings, J. F., Phimmachanh, M., Fey, D., Kölch, W., & Croucher, D. R. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050395 · Cited by 12
Deregulation of Transcriptional Enhancers in Cancer
Azad, F. M., & Atlasi, Y. (2021) · Cancers · doi:10.3390/cancers13143532 · Cited by 12
Pani
Chua, H.-E., Zhao, Q., Bhowmick, S. S., Dewey, C. F., Tucker‐Kellogg, L., & Yu, H. (2011) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/2147805.2147836 · Cited by 11
Integrative biology — a strategy for systems biomedicine
Liu, E. T. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2488 · Cited by 11
Self-citation
DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a
Zhou, Y., Perez, R. E., Duan, L., & Maki, C. G. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1433500 · Cited by 11
Epigenetics and Ovarian Cancer
Nephew, K. P., Balch, C., Zhang, S., & Huang, T. H. ‐. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-98094-2_6 · Cited by 11
Highly efficient generation of glutamatergic/cholinergic NT2-derived postmitotic human neurons by short-term treatment with the nucleoside analogue cytosine β- d -arabinofuranoside
González‐Burguera, I., Ricobaraza, A., Aretxabala, X., Barrondo, S., del Caño, G. G., de Jesús, M. L., & Sallés, J. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.02.038 · Cited by 11
Recent Advances in enhancer of zeste homolog 2 Inhibitors: Structural insights and therapeutic applications
Cao, R., Ni, J., Zhang, X., Qi, M., Zhang, Z., Liu, Z., & Chen, G. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108070 · Cited by 10
Dual targeting of EZH2 and PD-L1 in Burkitt’s lymphoma enhances immune activation and induces apoptotic pathway
Jeong, Y., Jang, H., Kim, S. B., Yu, M., Kim, R. W., Choi, W.-S., Jeon, Y., & Lim, J.-Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1578665 · Cited by 10
Enhancer of Zeste Homolog 2 (EZH2) Mediates Glucolipotoxicity-Induced Apoptosis in β-Cells
Dahlby, T., Simon, C., Backe, M. B., Dahllöf, M. S., Holson, E. B., Wagner, B. K., Böni‐Schnetzler, M., Marzec, M., Lundh, M., & Mandrup-Poulsen, T. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218016 · Cited by 10
Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies
Okosun, J., Packham, G., & Fitzgibbon, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.923402 · Cited by 12
Noncoding RNAs: Different roles in tumorigenesis
Lin, M., Wu, J., & Shan, G. (2012) · Chinese Science Bulletin · doi:10.1007/s11434-011-4917-x · Cited by 10
Targeting components of epigenome by small molecules
You, J. S., & Han, J. H. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0455-9 · Cited by 10
3-Deazaneplanocin A suppresses aggressive phenotype-related gene expression in an oral squamous cell carcinoma cell line
Hatta, M., Naganuma, K., Kato, K., & Yamazaki, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.115 · Cited by 10
The Role of Histone Methylation and Methyltransferases in Gene Regulation
Cui, J. Y., Fu, Z. D., & Dempsey, J. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812433-8.00002-2 · Cited by 11
A new kinetochore component CENP-W interacts with the polycomb-group protein EZH2 to promote gene silencing
Koh, W., Park, B., & Lee, S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.136 · Cited by 10
H3K27me3 of Rnf19a promotes neuroinflammatory response during Japanese encephalitis virus infection
Zhu, S., Tao, M., Li, Y., Wang, X., Zhao, Z., Liu, Y., Li, Q., Li, Q., Lu, Y., Si, Y., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02852-4 · Cited by 9
Druggable Molecular Networks in BRCA1/BRCA2-Mutated Breast Cancer
Carbone, F. P., Ancona, P., Volinia, S., Terrazzan, A., & Bianchi, N. (2025) · Biology · doi:10.3390/biology14030253 · Cited by 9
Selected small molecules as inductors of pluripotent stem cells
Baranek, M., Markiewicz, W. T., & Barciszewski, J. (2016) · Acta Biochimica Polonica · doi:10.18388/abp.2016_1363 · Cited by 9
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma
Qiang, N., Ao, J., Nakamura, M., Chiba, T., Kusakabe, Y., Kaneko, T., Kurosugi, A., Kogure, T., Ma, Y., Zhang, J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110068 · Cited by 11
Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatography–tandem mass spectrometric detection
Sun, F., Ong, J. C.-L., Yu, Q., & Chan, E. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.12.009 · Cited by 9
Self-citation
Epigenetics, Nervous System Tumors, and Cancer Stem Cells
Qureshi, I., & Mehler, M. F. (2011) · Cancers · doi:10.3390/cancers3033525 · Cited by 10
Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells
Yamamuro, S., Sano, E., Okamoto, Y., Ochiai, Y., OHTA, T., Ogino, A., Natsume, A., Wakabayashi, T., UEDA, T., Hara, H., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3165 · Cited by 9
Decreased expression of EZH2 reactivates RASSF2A by reversal of promoter methylation in breast cancer cells
Yu, P., Guo, Y., Maimaiti, Y., Liu, Z., Wang, S., Yin, X., Peng, G., Wang, L., Zhao, X., Guo, H., et al. (2016) · Cell Biology International · doi:10.1002/cbin.10646 · Cited by 9
An epigenetic regulatory element of the Nodal gene in the mouse and human genomes
Arai, D., Hayakawa, K., Ohgane, J., Hirosawa, M., Nakao, Y., Tanaka, S., & Shiota, K. (2014) · Mechanisms of Development · doi:10.1016/j.mod.2014.12.003 · Cited by 9
Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke
Qureshi, I., & Mehler, M. F. (2010) · Translational Stroke Research · doi:10.1007/s12975-010-0051-3 · Cited by 9
Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Sia, K. C., Huynh, H. T., Chung, A. Y. F., Ooi, L. L., Lim, K. H., Hui, K. M., & Lam, P. Y. P. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0056 · Cited by 9
Preliminary Study of the Role F-Box Protein 32 (FBXO32) in Colorectal Neoplasms Through the Transforming Growth Factor beta (TGF-β)/Smad4 Signalling Pathway
Yuan, X., Zhang, Z., Jiang, K.-T., Wang, X., & Li, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.908030 · Cited by 9
Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer
Zheng, N., Wang, L., Hou, Y., Zhou, X., He, Y., & Wang, Z. P. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1542897 · Cited by 9
Polycomb group proteins – epigenetic repressors with emerging roles in melanocytes and melanoma
Huang, J. M., & Hornyak, T. J. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12341 · Cited by 9
EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2
Xie, W., Chu, Q., Brea, L. T., Zeng, G., Wang, Y., Lü, X., Zheng, M., Ley, C. R., Lei, Z., Shi, H., et al. (2026) · Oncogene · doi:10.1038/s41388-025-03662-z · Cited by 11
Chemical and biochemical approaches in the study of histone methylation and demethylation
Li, K. K., Luo, C., Wang, D., Jiang, H., & Zheng, Y. G. (2010) · Medicinal Research Reviews · doi:10.1002/med.20228 · Cited by 8
Beyond conflict: Kinship theory of intragenomic conflict predicts individual variation in altruistic behaviour
Bresnahan, S. T., Galbraith, D. A., Ma, R., Anton, K., Rangel, J., & Grozinger, C. M. (2023) · Molecular Ecology · doi:10.1111/mec.17145 · Cited by 7
EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor
Sprinzen, L., Garcia, F., Mela, A., Lei, L., Upadhyayula, P. S., Mahajan, A., Humala, N., Manier, L., Caprioli, R. M., Quiñones‐Hinojosa, A., et al. (2024) · Cells · doi:10.3390/cells13030219 · Cited by 8
Distinct Epigenetic Mechanisms DistinguishTMPRSS2–ERG Fusion-Positive and -Negative Prostate Cancers
Alumkal, J. J., & Herman, J. G. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0392 · Cited by 8
The Pivotal Immunomodulatory and Anti-Inflammatory Effect of Histone-Lysine N-Methyltransferase in the Glioma Microenvironment: Its Biomarker and Therapy Potentials
Richard, S. A., & Kuugbee, E. D. (2021) · Analytical Cellular Pathology · doi:10.1155/2021/4907167 · Cited by 8
Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Sharma, A., Anderson, T. D., & Sharakhov, I. V. (2015) · Journal of Visualized Experiments · doi:10.3791/52041 · Cited by 8
Approaches to Target the Genome and Its Epigenome in Cancer
Chapman‐Rothe, N., & Brown, R. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.105 · Cited by 9

Authors: Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q.
Affiliations: Genome Institute of Singapore (SG)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Duke-NUS Medical School (SG)
ORCID: Tan, Jing
Yang, Xiaojing
Zhuang, Li
Jiang, Xia
Chen, Wei
Lee, Puay Leng
Karuturi, R.K. Murthy
Liu, Edison T.
Yu, Qiang
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2007-04-16
Volume: 21
Issue: 9
Pages: 1050-1063
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.1524107
PMC: PMC1855231
OpenAlex: W2113634596
Cited by: 895
References: 68
Citations by year: 2026: 12 · 2025: 16 · 2024: 18 · 2023: 35 · 2022: 21 · 2021: 35 · 2020: 39 · 2019: 37 · 2018: 44 · 2017: 65 · 2016: 55 · 2015: 65 · 2014: 98 · 2013: 77 · 2012: 70
Type: posted content
Language: en
Open access: bronze
doi.org
Locations: Genes & Development (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
National University of Singapore (submittedVersion)
Funders: Agency for Science, Technology and Research
National Cancer Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords: polycomb repressive complex 2, DZNep, EZH2, SUZ12, EED, histone H3 lysine 27 methylation, gene silencing, apoptosis, breast cancer, atrogin-1, chromatin remodeling, cancer therapy
MeSH terms: Adenosine, Base Sequence, Breast Neoplasms, Enzyme Inhibitors, Female, Histones, Humans, Methylation, Promoter Regions, Genetic, Repressor Proteins, RNA Polymerase II, Apoptosis, RNA Interference, RNA, Small Interfering, Chromatin Assembly and Disassembly, Adenosylhomocysteinase, Epigenesis, Genetic, Cell Line, Tumor, Chromatin Immunoprecipitation, Polycomb-Group Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks